Meniscal allograft transplantation performed in combination with treatment of focal articular cartilage lesions




    Policies Impacted
    Meniscal Allograft Transplantation #: 11.14.03e
    Musculoskeletal Services #: 00.01.66a

    Purpose
    The purpose of this communication is to provide notice regarding coverage position of meniscal allograft transplantation performed in combination with treatment of focal articular cartilage lesions.

    Background
    Meniscal allografts and other meniscal implants (e.g., collagen) are intended to improve symptoms and reduce joint degeneration in individuals who have had a total or partial meniscus resection. Meniscal allograft transplantation (MAT) is considered a salvage procedure, reserved for individuals with disabling knee pain following meniscectomy who are considered too young to undergo total knee arthroplasty (TKA) or in individuals who require a total or near total meniscectomy for irreparable tears. As a result, the population intended to receive these transplants is relatively limited. Although MAT can be performed by itself to meet clinical needs, meniscal allograft transplantation may be clinically indicated when performed in combination, either concurrently or sequentially, with treatment of focal articular cartilage lesions using procedures of autologous chondrocyte implantation, osteochondral allografting, or osteochondral autografting; when the latter treatments are also medically necessary.

    Coverage Statement
    Meniscal allograft transplantation is considered medically necessary and, therefore, covered when criteria in Company's medical policy entitled Meniscal Allograft Transplantation (Policy #: 11.14.03) are met. Furthermore, meniscal allograft transplantation is considered medically necessary and, therefore, covered when performed in combination, either concurrently or sequentially, with treatment of focal articular cartilage lesions using any of the procedures listed below; when clinical criteria for medical necessity are met for each of the individual procedures (i.e. meniscal allograft transplantation AND one of these three procedures):
    • autologous chondrocyte implantation, or
    • osteochondral allografting, or
    • osteochondral autografting.


    Coding
    29868

    Issued on - 05/14/2018

Connect with Us        


2017 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.